Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin added to insulin in Asian subjects with T2D
NCT02096705Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Mar 2014; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02096705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096705.